Giant cell arteritis: a multicenter observational study in Brazil
- PMID: 23644850
- PMCID: PMC3611879
- DOI: 10.6061/clinics/2013(03)oa06
Giant cell arteritis: a multicenter observational study in Brazil
Abstract
Objective: To describe demographic features, disease manifestations and therapy in patients with giant cell arteritis from referral centers in Brazil.
Methods: A retrospective cohort study was performed on 45 giant cell arteritis patients from three university hospitals in Brazil. Diagnoses were based on the American College of Rheumatology classification criteria for giant cell arteritis or temporal artery biopsy findings.
Results: Most patients were Caucasian, and females were slightly more predominant. The frequencies of disease manifestations were as follows: temporal headache in 82.2%, neuro-ophthalmologic manifestations in 68.9%, jaw claudication in 48.9%, systemic symptoms in 44.4%, polymyalgia rheumatica in 35.6% and extra-cranial vessel involvement in 17.8% of cases. Aortic aneurysms were observed in 6.6% of patients. A comparison between patients with biopsy-proven giant cell arteritis and those without temporal artery biopsies did not yield significant differences in disease manifestations. All patients were treated with oral prednisone, and intravenous methylprednisolone was administered to nearly half of the patients. Methotrexate was the most commonly used immunosuppressive agent, and low-dose aspirin was prescribed to the majority of patients. Relapses occurred in 28.9% of patients, and aspirin had a protective effect against relapses. Females had higher prevalences of polymyalgia rheumatica, systemic manifestations and jaw claudication, while permanent visual loss was more prevalent in men.
Conclusions: Most of the clinical features of Brazilian giant cell arteritis patients were similar to those found in other studies, except for the high prevalence of neuro-ophthalmic manifestations and permanent blindness in the Brazilian patients. Aspirin had a protective effect on relapses.
Conflict of interest statement
No potential conflict of interest was reported.
Similar articles
-
Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica.Am J Med. 1997 Apr;102(4):331-6. doi: 10.1016/s0002-9343(97)00117-4. Am J Med. 1997. PMID: 9217613
-
[Giant cell arteritis. A study of 191 patients].Med Clin (Barc). 1995 Dec 2;105(19):734-7. Med Clin (Barc). 1995. PMID: 8523954 Review. Spanish.
-
Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica.Arthritis Rheum. 1994 Nov;37(11):1621-6. doi: 10.1002/art.1780371111. Arthritis Rheum. 1994. PMID: 7980674
-
Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings.Ann Intern Med. 1972 Dec;77(6):845-52. doi: 10.7326/0003-4819-77-6-845. Ann Intern Med. 1972. PMID: 4644163 No abstract available.
-
Clinical features of polymyalgia rheumatica and giant cell arteritis.Nat Rev Rheumatol. 2012 Sep;8(9):509-21. doi: 10.1038/nrrheum.2012.97. Epub 2012 Jul 24. Nat Rev Rheumatol. 2012. PMID: 22825731 Review.
Cited by
-
A Retrospective Study of Chinese Patients With Giant Cell Arteritis (GCA): Clinical Features and Factors Associated With Severe Ischemic Manifestations.Medicine (Baltimore). 2016 Mar;95(13):e3213. doi: 10.1097/MD.0000000000003213. Medicine (Baltimore). 2016. PMID: 27043686 Free PMC article.
-
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.Rheumatology (Oxford). 2016 Feb;55(2):347-56. doi: 10.1093/rheumatology/kev348. Epub 2015 Sep 18. Rheumatology (Oxford). 2016. PMID: 26385368 Free PMC article.
-
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.RMD Open. 2023 Jun;9(2):e003233. doi: 10.1136/rmdopen-2023-003233. RMD Open. 2023. PMID: 37349123 Free PMC article.
-
Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.J Transl Autoimmun. 2020 Nov 28;3:100072. doi: 10.1016/j.jtauto.2020.100072. eCollection 2020. J Transl Autoimmun. 2020. PMID: 33305250 Free PMC article.
-
Rare association between giant-cell aortitis and giant-cell aortic valvulitis.Autops Case Rep. 2023 Oct 23;13:e2023449. doi: 10.4322/acr.2023.449. eCollection 2023. Autops Case Rep. 2023. PMID: 38034520 Free PMC article.
References
-
- Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–45. - PubMed
-
- Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Eng J Med. 2002;347(4):261–71. - PubMed
-
- Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11(6-7):A544–54. - PubMed
-
- Gonzales-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454–61. - PubMed
-
- Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculitis. Best Pract Res Clin Rheumatol. 2010;24(6):871–83. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical